Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
AZ 32 is an inhibitor of ataxia-telangiectasia mutated (ATM) kinase (IC50 = <6.2 nM).1 It is selective for ATM over PI3Kα and ataxia-telangiectasia and Rad3-related (ATR) kinase (IC50s = 4.6 and >4.6 µM, respectively). AZ 32 enhances radiation-induced cytotoxicity in a panel of five human glioma cells expressing wild-type or mutant p53. It increases survival in a U87-281G glioma orthotopic mouse xenograft model, as well as a NCI H2228 non-small cell lung cancer (NSCLC) mouse xenograft model of metastatic brain tumors, when administered at doses of 200 and 50 mg/kg, respectively, in combination with ionizing radiation.
WARNING This product is not for human or veterinary use.
1. Orally bioavailable and blood-